Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$128.11
0.0%
$109.27
$73.04
$128.45
$8.28B0.841.30 million shs2.99 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$15.10
-1.6%
$14.77
$11.51
$21.50
$2.67B0.52100,388 shs37,205 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.16
-1.4%
$26.36
$23.15
$129.39
$10.65B1.868.56 million shs11.54 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$93.82
-0.6%
$78.39
$14.14
$99.01
$8.04B0.211.27 million shs951,387 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-0.03%-0.07%+34.43%+44.40%+23.28%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-1.56%+1.75%+14.13%-0.98%-15.26%
Moderna, Inc. stock logo
MRNA
Moderna
-1.38%+4.86%+4.26%-12.72%-77.82%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-0.61%-0.53%+26.90%+49.63%+538.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.6991 of 5 stars
2.14.00.00.02.80.80.6
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.7051 of 5 stars
3.04.00.00.02.00.01.9
Moderna, Inc. stock logo
MRNA
Moderna
4.5345 of 5 stars
4.02.00.04.61.42.51.3
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.8067 of 5 stars
2.51.00.00.03.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.27
Hold$128.06-0.04% Downside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.00
Hold$19.0025.83% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6171.62% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3.00
Buy$101.107.76% Upside

Current Analyst Ratings Breakdown

Latest HCM, MRNA, BPMC, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$76.00 ➝ $160.00
6/20/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $138.00
6/18/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$92.00 ➝ $116.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $100.00
6/11/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $110.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$132.00
6/3/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$508.82M16.26N/AN/A$4.70 per share27.26
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.18$0.28 per share53.41$4.43 per share3.41
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.25N/AN/A$28.33 per share0.96
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$42.28M188.90N/AN/A$2.56 per share36.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A197.09N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0010.34N/AN/AN/AN/A7/29/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$2.00N/A3,127.33N/AN/A-69.65%-28.00%8/6/2025 (Estimated)

Latest HCM, MRNA, BPMC, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
4/29/2025Q1 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.07
8.86
8.73

Institutional Ownership

CompanyInstitutional Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
85.88%

Insider Ownership

CompanyInsider Ownership
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
4.21%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.32 million168.05 millionNot Optionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3085.13 million81.05 millionOptionable

Recent News About These Companies

Verona Pharma: An Impressive Initial Launch

New MarketBeat Followers Over Time

Media Sentiment Over Time

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$128.11 -0.04 (-0.03%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$128.01 -0.10 (-0.08%)
As of 06/27/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$15.10 -0.24 (-1.56%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$15.11 +0.01 (+0.07%)
As of 06/27/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.16 -0.38 (-1.38%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$27.16 0.00 (-0.02%)
As of 06/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$93.82 -0.58 (-0.61%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$93.51 -0.31 (-0.33%)
As of 06/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.